BLRX.TA - BioLineRx Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
250.10
-4.40 (-1.73%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close254.50
Open252.00
Bid263.00 x 255900
Ask241.80 x 42900
Day's Range250.10 - 255.30
52 Week Range250.10 - 580.00
Volume109,571
Avg. Volume188,419
Market Cap270.316M
Beta (3Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateAug 8, 2018 - Aug 15, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • PR Newswire7 days ago

    BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update

    Management to hold conference call at 10:00 am EST TEL AVIV, Israel , Nov. 8, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology ...

  • PR Newswire27 days ago

    BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

    BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer Encouraging results support further development ...

  • Can The Uptrend Continue for BioLineRx (BLRX)?
    Zackslast month

    Can The Uptrend Continue for BioLineRx (BLRX)?

    Investors certainly have to be happy with BioLineRx Ltd. (BLRX) and its short term performance.

  • BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher
    Zackslast month

    BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher

    BioLineRx (BLRX) shares rose nearly 8% in the last trading session, amid huge volumes.

  • BioLineRx Stock Up on Stake Increase in Lead Cancer Program
    Zackslast month

    BioLineRx Stock Up on Stake Increase in Lead Cancer Program

    BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.

  • PR Newswirelast month

    BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications

    TEL AVIV, Israel, Oct. 3, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has entered into an agreement with Biokine Therapeutics to increase BioLineRx's stake in its lead oncology platform, BL-8040, a CXCR4 antagonist currently in late stage clinical development in both solid tumor and hematological indications, including stem cell mobilization (SCM), acute myeloid leukemia (AML) and immunotherapy for multiple types of solid tumors. As a result of the transaction, BioLineRx will increase its economic stake in the program to 80% from the previous level of 60%.

  • BioLineRx (BLRX) Continue to Surge Higher?
    Zacks2 months ago

    BioLineRx (BLRX) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in BioLineRx Ltd. (BLRX).

  • PR Newswire3 months ago

    BioLineRx Reports Second Quarter 2018 Financial Results

    TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...

  • PR Newswire3 months ago

    BioLineRx to Report Second Quarter 2018 Results on August 13, 2018

    TEL AVIV, Israel, Aug. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended June 30, 2018 on Monday, August 13, 2018, before the US markets open. The Company will host a conference call on Monday, August 13, 2018 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.

  • PR Newswire4 months ago

    BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

    TEL AVIV, Israel, July 30, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the expansion of its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) for the support of a Phase 2a program investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA, in patients with metastatic pancreatic cancer. Under the expansion, a triple combination arm investigating the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy will be added to the ongoing COMBAT/KEYNOTE-202 study.

  • Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
    Zacks4 months ago

    Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

    Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

  • BioLineRx Sees Hammer Chart Pattern: Time to Buy?
    Zacks5 months ago

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

  • PR Newswire5 months ago

    BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients

    TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that new data presented at the 23rd Annual Congress of the European Hematology Association (EHA), held in Stockholm, Sweden, shows that BL-8040, combined with high dose cytarabine (HiDAC), significantly enhanced overall survival in difficult-to-treat relapsed or refractory AML (r/r AML) patients in a Phase 2a clinical trial.

  • PR Newswire5 months ago

    BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference

    TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire6 months ago

    BioLineRx Reports First Quarter 2018 Financial Results

    TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...

  • PR Newswire6 months ago

    BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation

    TEL AVIV, Israel, May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from a Phase 2 clinical trial assessing BL-8040 as a single agent for hematopoietic stem cell mobilization in an allogeneic transplantation setting. Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure. This proof-of-concept Phase 2 study, consisting of 24 donor/recipient pairs, assesses the ability of BL-8040 monotherapy to mobilize HSPCs for transplantation in a single administration.

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Biolinerx Ltd/S ADR (NASDAQ: BLRX ) stock was trading ...

  • Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
    Zacks7 months ago

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

  • PR Newswire8 months ago

    BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors

    TEL AVIV, Israel, March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of AGI-134, a novel immunotherapy compound, for the treatment of solid cancer tumors. This patent, when issued, will be valid until May 2035 with a possibility of up to five years patent term extension. Additional corresponding patent applications for AGI-134 are pending in Europe, Japan, China, Canada, Australia and Israel.

  • PR Newswire8 months ago

    BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference

    TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire8 months ago

    BioLineRx Reports Year End 2017 Financial Results

    TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire9 months ago

    BioLineRx to Report Annual 2017 Results on March 6, 2018

    Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...

  • PR Newswire9 months ago

    BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13

    TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
    Zacks10 months ago

    BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

    BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.

  • PR Newswire10 months ago

    BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer

    TEL AVIV, Israel, Jan. 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study showing that BL-8040 increases infiltration of T cells into the tumor in patients with metastatic pancreatic cancer. The data will be presented as a poster titled "Evaluation of Pharmacodynamic Biomarkers in Patients with Metastatic Pancreatic Cancer Treated with BL-8040, a Novel CXCR4 Antagonist (Abstract 276)" at the ASCO 2018 Gastrointestinal Cancers Symposium, on January 19, 2018 in San Francisco, CA.